AbbVie Must Detail Efforts To Kneecap Humira Biosimilars

Law360 (February 8, 2019, 10:52 PM EST) -- AbbVie Inc. has thrown "wrenches into the gears" of high-stakes patent litigation over its hugely popular immunosuppressant Humira, a Delaware magistrate judge said Friday, ordering the drugmaker to swiftly detail any efforts to cripple biosimilar competition.

In a blistering opinion, U.S. Magistrate Judge Richard A. Lloret found that AbbVie hasn't come close to complying with a discovery order issued eight months ago in patent litigation with Boehringer Ingelheim over Humira, which earned $20 billion last year and is the world's best-selling drug.

Although AbbVie coughed up some documents, Boehringer identified 14 categories where compliance was lacking, and Judge Lloret on Friday...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS